Novozymes Balance Sheet Health
Financial Health criteria checks 4/6
Novozymes has a total shareholder equity of DKK14.4B and total debt of DKK7.4B, which brings its debt-to-equity ratio to 51.6%. Its total assets and total liabilities are DKK28.4B and DKK14.0B respectively. Novozymes's EBIT is DKK4.5B making its interest coverage ratio 53.8. It has cash and short-term investments of DKK1.1B.
Key information
51.6%
Debt to equity ratio
kr.7.41b
Debt
| Interest coverage ratio | 53.8x |
| Cash | kr.1.12b |
| Equity | kr.14.35b |
| Total liabilities | kr.14.04b |
| Total assets | kr.28.39b |
Recent financial health updates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Recent updates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued
Sep 05Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
May 02Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Apr 07Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?
Mar 12Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues
Feb 04Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jan 29Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture
Dec 05A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Oct 14These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence
Aug 29Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jul 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
May 29Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Apr 12Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 01Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
Feb 14Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?
Jan 01We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt
Nov 28Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital
Nov 11Financial Position Analysis
Short Term Liabilities: NSIS B's short term assets (DKK9.5B) exceed its short term liabilities (DKK7.3B).
Long Term Liabilities: NSIS B's short term assets (DKK9.5B) exceed its long term liabilities (DKK6.8B).
Debt to Equity History and Analysis
Debt Level: NSIS B's net debt to equity ratio (43.9%) is considered high.
Reducing Debt: NSIS B's debt to equity ratio has increased from 28.5% to 51.6% over the past 5 years.
Debt Coverage: NSIS B's debt is well covered by operating cash flow (56%).
Interest Coverage: NSIS B's interest payments on its debt are well covered by EBIT (53.8x coverage).